• Most common adverse events for Cymbalta vs placebo during controlled clinical trials for DPNP included: nausea, somnolence, dizziness, constipation, dry mouth, increased sweating, decreased appetite, and asthenia.

Cymbalta—a proven option for diabetic peripheral neuropathic pain (DPNP)

Proven—Rapid relief that has been replicated in 2 separate and distinct clinical trials

• First FDA-approved agent for the management of DPNP
In night pain reported by patients, Cymbalta demonstrated significant separation from placebo as early as week 1, and improvement continued throughout the 12-week study.

The period of postictal confusion can last for up to 2 weeks in elderly patients, compared with just a few seconds or minutes in younger patients.

In such patients who have had at least two seizures, the diagnosis can be made in the elderly after just one seizure; 90% of elderly patients who have had one seizure will have a second unless they are treated.

Among the other differences between epilepsy in the young and the elderly, he added, is that epilepsy in the elderly, while extremely common, is manifested by a low rate of seizures. Yet in the elderly the postictal state after complex partial seizures tends to be prolonged. The period of confusion can last up to 2 weeks, compared with a minute or so in infants and youngsters.

In most cases, epilepsy in the elderly develops secondary to cerebrovascular disease, said Dr. Rowan.

Cerebral infarctions account for nearly 40% of cases of new onset epilepsy. Multivessel atherosclerosis, cerebral hemorrhage, and subarachnoid hemorrhage make up another 10%. Approximately 30% of cases are of unknown etiology. About 20% of cases were Alzheimer’s patients. Drugs such as theophylline lower the seizure threshold.

Cymbalta—an effective way to manage DPNP

Effective—rapid relief at night of DPNP

*As measured by an 11-point Likert scale.

†24-hour night pain severity—the average night pain severity experienced by the patient in the previous 24 hours (collected daily and averaged by week).

See Important Safety Information on cover page of advertisement and Brief Summary of full Prescribing Information at the end of this advertisement.